Welcome to our dedicated page for AtriCure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AtriCure's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AtriCure's regulatory disclosures and financial reporting.
AtriCure Inc reports an institutional holding: Vanguard Capital Management beneficially owns 2,532,965 shares of common stock, representing 5.08% of the class.
The Schedule 13G lists voting and dispositive powers: sole power to vote 377,201 shares and sole dispositive power over 2,532,965 shares. The filing names affiliated Vanguard entities and is signed by a Vanguard officer.
AtriCure Inc reported a Schedule 13G filing showing Vanguard Portfolio Management beneficially owns 2,744,685 shares of Common Stock. The filing states this equals 5.51% of the class as of 03/31/2026 and that Vanguard Portfolio Management has sole dispositive power over 2,744,685 shares and sole voting power for 42,053 shares.
The filing attributes holdings to Vanguard Portfolio Management LLC and affiliated business divisions and is signed on behalf of Vanguard by Ashley Grim on 04/28/2026.
AtriCure, Inc. is asking stockholders to approve several items at its virtual 2026 annual meeting, including amendments to expand its equity compensation plans. The company seeks to add 1,500,000 shares to the 2023 Stock Incentive Plan and 750,000 shares to the 2018 Employee Stock Purchase Plan.
Stockholders are also being asked to elect nine directors for one-year terms, ratify Deloitte & Touche LLP as independent auditor for 2026, and approve an advisory "say-on-pay" vote on named executive officer compensation. The meeting will be held online on May 18, 2026; holders of AtriCure common stock as of March 26, 2026, when 50,634,808 shares were outstanding, are entitled to vote.
AtriCure Inc Schedule 13G/A Amendment No. 6: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0%. The filing notes an internal realignment on January 12, 2026 that disaggregated reporting by Vanguard subsidiaries. The amendment is signed by Ashley Grim on 03/26/2026.
AtriCure, Inc. Chief Scientific Officer Doraiswamy Vinayak reported an open-market sale of 5,000 shares of common stock. The shares were sold at a weighted average price of $29.83 per share, in multiple trades executed between $29.79 and $29.92. Following this transaction, he directly holds 96,875 shares of AtriCure common stock.
ATRC submitted a Form 144 notice reporting proposed sales of common stock awards. The filing lists Performance Shares: 1,561 with an award date of 03/01/2024 and three Restricted Stock items of 813, 1,578, and 1,048 shares with award dates of 03/01/2023 and 03/01/2024.
The securities are identified as being sold by the Issuer and are reported for sale under Rule 144; timing and cash‑flow treatment are not stated in the excerpt.
AtriCure, Inc. director Robert S. White exercised non-qualified stock options for 10,000 shares at $14.99 per share. These options were originally granted on May 25, 2016 and vested over four years. Following the exercise, he directly holds 122,174 shares of AtriCure common stock.
AtriCure, Inc. President, CEO, and Director Michael H. Carrel reported bona fide gifts totaling 6,000 shares of AtriCure common stock on March 6, 2026, consisting of separate transfers of 5,000 shares and 1,000 shares. No consideration was received for these gifts to his children and sibling, and his directly owned stake was reported as 778,498 shares following the gifts. He also reported indirect holdings held by his children, parents, and sibling, and disclaimed beneficial ownership of those indirect holdings except for his pecuniary interest.
AtriCure, Inc. President and CEO Michael H. Carrel reported equity compensation and related tax withholding transactions in AtriCure common stock. On March 1, 2026, he acquired 68,618 shares through a restricted stock award under the AtriCure, Inc. 2023 Stock Incentive Plan, with one third of the shares vesting on each of the first, second, and third anniversaries of the grant date.
He also acquired 101,280 shares upon the vesting and release of a performance share award under the same 2023 plan, after the company performance goals and required service period were met. To cover tax withholding obligations from vesting awards, he transferred 72,777 shares back to the company at $31.26 per share, characterized as a tax-withholding disposition. After these direct transactions, he directly held 784,498 shares of common stock.
In addition, Form 4 reflects 9,310 shares held indirectly by his children and 2,250 shares held indirectly by his parents. A footnote states he disclaims beneficial ownership of these indirectly held securities, except to the extent of his pecuniary interest.
AtriCure, Inc. Chief Marketing & Strategy Officer Justin J. Noznesky reported equity compensation and related tax withholding in company stock. He acquired 27,991 shares through a new restricted stock award and 15,198 shares from a performance share award that vested after meeting company performance and service requirements. To cover tax obligations on vested awards, he transferred 15,586 shares back to the company at a price of $31.26 per share, leaving him with 106,401 shares of common stock held directly.